Skip to main content
Healthcare Forum 2024 Main banner
Back

Tom Hawes

Partner
Sandbox Clinical Ventures and Blue Venture Fund

Dr. Tom Hawes joined Sandbox in 2008 and is a Partner of Sandbox Clinical Ventures and the Blue Venture Funds. He currently serves on the board of directors of First Dollar, Octave Bioscience, Owl Insights, and Upward Health. Dr. Hawes previously served as a board member of AbleTo (acquired by Optum), Healthify (acquired by Wellsky), HeartFlow, InVivoLink (acquired by HCA), PatientCo (acquired by WayStar), Nexidia (acquired by NICE), OncoHealth (acquired by Arsenal Capital Partners and McKesson), Phreesia (NYSE: PHR), and Verata Health (acquired by Olive.Ai), and as a board observer of Thrive Earlier Detection (NASDAQ: EXAS).

Prior to Sandbox, Dr. Hawes matched at Yale School of Medicine for residency. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and New York Medical College’s Cardiothoracic Surgery Department.
Dr. Hawes holds an MD from New York Medical College, an MBA from Harvard Business School, and a BA from Brigham Young University. He is also a Kauffman Fellow.

Presentation(s):